ID   HCK_HUMAN               Reviewed;         526 AA.
AC   P08631; A8K1I1; B4DQB6; E1P5M2; Q29RX1; Q2VPE2; Q504R5; Q5T7K1; Q5T7K2;
AC   Q96CC0; Q9H5Y5; Q9NUA4; Q9UMJ5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   12-OCT-2022, entry version 263.
DE   RecName: Full=Tyrosine-protein kinase HCK;
DE            EC=2.7.10.2;
DE   AltName: Full=Hematopoietic cell kinase;
DE   AltName: Full=Hemopoietic cell kinase;
DE   AltName: Full=p59-HCK/p60-HCK;
DE   AltName: Full=p59Hck;
DE   AltName: Full=p61Hck;
GN   Name=HCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3496523; DOI=10.1128/mcb.7.6.2267-2275.1987;
RA   Quintrell N., Lebo R., Varmus H., Bishop J.M., Pettenati M.J.,
RA   le Beau M.M., Diaz M.O., Rowley J.D.;
RT   "Identification of a human gene (HCK) that encodes a protein-tyrosine
RT   kinase and is expressed in hemopoietic cells.";
RL   Mol. Cell. Biol. 7:2267-2275(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=3453117; DOI=10.1128/mcb.7.6.2276-2285.1987;
RA   Ziegler S.F., Marth J.D., Lewis D.B., Perlmutter R.M.;
RT   "Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells
RT   of hematopoietic origin.";
RL   Mol. Cell. Biol. 7:2276-2285(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4), AND VARIANT
RP   LEU-105.
RC   TISSUE=Corpus callosum, and Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=B-cell, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1), AND ALTERNATIVE INITIATION.
RC   TISSUE=Bone marrow;
RX   PubMed=1875927; DOI=10.1128/mcb.11.9.4363-4370.1991;
RA   Lock P., Ralph S., Stanley E., Boulet I., Ramsay R., Dunn A.R.;
RT   "Two isoforms of murine hck, generated by utilization of alternative
RT   translational initiation codons, exhibit different patterns of subcellular
RT   localization.";
RL   Mol. Cell. Biol. 11:4363-4370(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 178-526.
RC   TISSUE=Spleen;
RX   PubMed=1572549; DOI=10.1016/0378-1119(92)90407-g;
RA   Hradetzky D., Strebhardt K., Ruesamen-Waigmann H.;
RT   "The genomic locus of the human hemopoietic-specific cell protein tyrosine
RT   kinase (PTK)-encoding gene (HCK) confirms conservation of exon-intron
RT   structure among human PTKs of the src family.";
RL   Gene 113:275-280(1992).
RN   [9]
RP   INTERACTION WITH FCGR2A, CATALYTIC ACTIVITY, AND FUNCTION IN
RP   PHOSPHORYLATION OF FCGR2A.
RX   PubMed=8132624; DOI=10.1016/s0021-9258(17)37050-3;
RA   Ghazizadeh S., Bolen J.B., Fleit H.B.;
RT   "Physical and functional association of Src-related protein tyrosine
RT   kinases with Fc gamma RII in monocytic THP-1 cells.";
RL   J. Biol. Chem. 269:8878-8884(1994).
RN   [10]
RP   INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8064233; DOI=10.1084/jem.180.3.1165;
RA   Wang A.V., Scholl P.R., Geha R.S.;
RT   "Physical and functional association of the high affinity immunoglobulin G
RT   receptor (Fc gamma RI) with the kinases Hck and Lyn.";
RL   J. Exp. Med. 180:1165-1170(1994).
RN   [11]
RP   FUNCTION IN FCGR1A SIGNALING, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND
RP   ACTIVITY REGULATION.
RX   PubMed=7535819;
RA   Durden D.L., Kim H.M., Calore B., Liu Y.;
RT   "The Fc gamma RI receptor signals through the activation of hck and MAP
RT   kinase.";
RL   J. Immunol. 154:4039-4047(1995).
RN   [12]
RP   SUBCELLULAR LOCATION, ALTERNATIVE INITIATION, MYRISTOYLATION AT GLY-2,
RP   MYRISTOYLATION AT GLY-2 (ISOFORM 2), PALMITOYLATION AT CYS-3 (ISOFORM 2),
RP   AND MUTAGENESIS OF GLY-3; GLY-23 AND CYS-24.
RX   PubMed=7791757; DOI=10.1128/mcb.15.7.3507;
RA   Robbins S.M., Quintrell N.A., Bishop J.M.;
RT   "Myristoylation and differential palmitoylation of the HCK protein-tyrosine
RT   kinases govern their attachment to membranes and association with
RT   caveolae.";
RL   Mol. Cell. Biol. 15:3507-3515(1995).
RN   [13]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION, AND INTERACTION WITH IL6ST.
RX   PubMed=9406996;
RA   Hallek M., Neumann C., Schaffer M., Danhauser-Riedl S., von Bubnoff N.,
RA   de Vos G., Druker B.J., Yasukawa K., Griffin J.D., Emmerich B.;
RT   "Signal transduction of interleukin-6 involves tyrosine phosphorylation of
RT   multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck,
RT   and Lyn in multiple myeloma cell lines.";
RL   Exp. Hematol. 25:1367-1377(1997).
RN   [14]
RP   INDUCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8995234; DOI=10.1074/jbc.272.1.102;
RA   Welch H., Maridonneau-Parini I.;
RT   "Hck is activated by opsonized zymosan and A23187 in distinct subcellular
RT   fractions of human granulocytes.";
RL   J. Biol. Chem. 272:102-109(1997).
RN   [15]
RP   ACTIVITY REGULATION, AND INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=9218412; DOI=10.1074/jbc.272.29.17899;
RA   Briggs S.D., Sharkey M., Stevenson M., Smithgall T.E.;
RT   "SH3-mediated Hck tyrosine kinase activation and fibroblast transformation
RT   by the Nef protein of HIV-1.";
RL   J. Biol. Chem. 272:17899-17902(1997).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AND INTERACTION WITH BCR-ABL.
RX   PubMed=9407116; DOI=10.1074/jbc.272.52.33260;
RA   Warmuth M., Bergmann M., Priess A., Hauslmann K., Emmerich B., Hallek M.;
RT   "The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent
RT   mechanism and phosphorylates the Grb2-binding site of Bcr.";
RL   J. Biol. Chem. 272:33260-33270(1997).
RN   [17]
RP   FUNCTION IN CBL PHOSPHORYLATION; CELL PROLIFERATION AND REGULATION OF CELL
RP   SHAPE, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-522, AND
RP   INTERACTION WITH CBL.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [18]
RP   FUNCTION IN IL2 SIGNALING, CATALYTIC ACTIVITY, INDUCTION, ACTIVITY
RP   REGULATION, AND PHOSPHORYLATION.
RX   PubMed=10779760; DOI=10.4049/jimmunol.164.9.4575;
RA   Bosco M.C., Curiel R.E., Zea A.H., Malabarba M.G., Ortaldo J.R.,
RA   Espinoza-Delgado I.;
RT   "IL-2 signaling in human monocytes involves the phosphorylation and
RT   activation of p59hck.";
RL   J. Immunol. 164:4575-4585(2000).
RN   [19]
RP   PHOSPHORYLATION AT TYR-411 AND TYR-522, IDENTIFICATION BY MASS
RP   SPECTROMETRY, ACTIVITY REGULATION, AND MUTAGENESIS OF GLU-305 AND TYR-411.
RX   PubMed=10644735; DOI=10.1074/jbc.275.4.2721;
RA   Porter M., Schindler T., Kuriyan J., Miller W.T.;
RT   "Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and
RT   Tyr(416). Effect of introducing a high affinity intramolecular SH2
RT   ligand.";
RL   J. Biol. Chem. 275:2721-2726(2000).
RN   [20]
RP   FUNCTION IN IL8-MEDIATED DEGRANULATION, ACTIVITY REGULATION, AND
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=10973280; DOI=10.1038/79767;
RA   Barlic J., Andrews J.D., Kelvin A.A., Bosinger S.E., DeVries M.E., Xu L.,
RA   Dobransky T., Feldman R.D., Ferguson S.S., Kelvin D.J.;
RT   "Regulation of tyrosine kinase activation and granule release through beta-
RT   arrestin by CXCRI.";
RL   Nat. Immunol. 1:227-233(2000).
RN   [21]
RP   INTERACTION WITH HIV-1 VIF (MICROBIAL INFECTION).
RX   PubMed=11278465; DOI=10.1074/jbc.m009076200;
RA   Hassaine G., Courcoul M., Bessou G., Barthalay Y., Picard C., Olive D.,
RA   Collette Y., Vigne R., Decroly E.;
RT   "The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted
RT   by the viral vif protein.";
RL   J. Biol. Chem. 276:16885-16893(2001).
RN   [22]
RP   INTERACTION WITH HEV ORF3 PROTEIN (MICROBIAL INFECTION).
RX   PubMed=11518702; DOI=10.1074/jbc.m101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and
RT   activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [23]
RP   FUNCTION AS EFFECTOR OF THE BCR-ABL FUSION PROTEIN IN PHOSPHORYLATION OF
RP   STAT5B, INTERACTION WITH STAT5B AND THE BCR-ABL FUSION PROTEIN, AND
RP   PHOSPHORYLATION.
RX   PubMed=12411494; DOI=10.1093/emboj/cdf562;
RA   Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A.,
RA   Wilson M., Smithgall T.E., Skorski T.;
RT   "The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid
RT   leukemia cells.";
RL   EMBO J. 21:5766-5774(2002).
RN   [24]
RP   INTERACTION WITH ADAM15, AND FUNCTION IN PHOSPHORYLATION OF ADAM15.
RX   PubMed=11741929; DOI=10.1074/jbc.m107430200;
RA   Poghosyan Z., Robbins S.M., Houslay M.D., Webster A., Murphy G.,
RA   Edwards D.R.;
RT   "Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain
RT   and Src family protein-tyrosine kinases.";
RL   J. Biol. Chem. 277:4999-5007(2002).
RN   [25]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON; FORMATION OF CELL
RP   PROTRUSIONS AND PHAGOCYTOSIS (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2),
RP   AND MUTAGENESIS OF GLY-3.
RX   PubMed=11904303; DOI=10.1074/jbc.m201212200;
RA   Carreno S., Caron E., Cougoule C., Emorine L.J., Maridonneau-Parini I.;
RT   "p59Hck isoform induces F-actin reorganization to form protrusions of the
RT   plasma membrane in a Cdc42- and Rac-dependent manner.";
RL   J. Biol. Chem. 277:21007-21016(2002).
RN   [26]
RP   FUNCTION IN CELL PROLIFERATION, UBIQUITINATION, PHOSPHORYLATION AT TYR-51;
RP   TYR-411 AND TYR-522, SUBCELLULAR LOCATION, INTERACTION WITH CBL (ISOFORM
RP   2), AND MUTAGENESIS OF LYS-290 AND TYR-522.
RX   PubMed=11896602; DOI=10.1038/sj.onc.1205228;
RA   Howlett C.J., Robbins S.M.;
RT   "Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated
RT   cellular transformation.";
RL   Oncogene 21:1707-1716(2002).
RN   [27]
RP   FUNCTION IN IL6 SIGNALING CASCADE AND IN PHOSPHORYLATION OF GAB1 AND GAB2.
RX   PubMed=15010462; DOI=10.1074/jbc.m305783200;
RA   Podar K., Mostoslavsky G., Sattler M., Tai Y.T., Hayashi T., Catley L.P.,
RA   Hideshima T., Mulligan R.C., Chauhan D., Anderson K.C.;
RT   "Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation
RT   of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation
RT   and survival of multiple myeloma cells.";
RL   J. Biol. Chem. 279:21658-21665(2004).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF ELMO1, AND INTERACTION WITH ELMO1.
RX   PubMed=15952790; DOI=10.1021/bi0500832;
RA   Yokoyama N., deBakker C.D., Zappacosta F., Huddleston M.J., Annan R.S.,
RA   Ravichandran K.S., Miller W.T.;
RT   "Identification of tyrosine residues on ELMO1 that are phosphorylated by
RT   the Src-family kinase Hck.";
RL   Biochemistry 44:8841-8849(2005).
RN   [29]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-381.
RX   PubMed=15998323; DOI=10.1111/j.1600-0854.2005.00307.x;
RA   Cougoule C., Carreno S., Castandet J., Labrousse A., Astarie-Dequeker C.,
RA   Poincloux R., Le Cabec V., Maridonneau-Parini I.;
RT   "Activation of the lysosome-associated p61Hck isoform triggers the
RT   biogenesis of podosomes.";
RL   Traffic 6:682-694(2005).
RN   [30]
RP   INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION), AND ACTIVITY REGULATION.
RX   PubMed=16849330; DOI=10.1074/jbc.m601128200;
RA   Trible R.P., Emert-Sedlak L., Smithgall T.E.;
RT   "HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src
RT   through direct SH3 domain interaction.";
RL   J. Biol. Chem. 281:27029-27038(2006).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION AND INHIBITION OF TP73 ACTIVITY, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH TP73 AND YAP1.
RX   PubMed=17535448; DOI=10.1186/1471-2199-8-45;
RA   Paliwal P., Radha V., Swarup G.;
RT   "Regulation of p73 by Hck through kinase-dependent and independent
RT   mechanisms.";
RL   BMC Mol. Biol. 8:45-45(2007).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH IL6ST.
RX   PubMed=17310994; DOI=10.1038/sj.onc.1210306;
RA   Hausherr A., Tavares R., Schaffer M., Obermeier A., Miksch C., Mitina O.,
RA   Ellwart J., Hallek M., Krause G.;
RT   "Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide
RT   repressing the gp130-mediated activation of Src family kinases.";
RL   Oncogene 26:4987-4998(2007).
RN   [33]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [34]
RP   FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON AND CELL PROLIFERATION,
RP   AND ROLE IN DISEASE.
RX   PubMed=19114024; DOI=10.1016/j.ejca.2008.11.020;
RA   Poincloux R., Al Saati T., Maridonneau-Parini I., Le Cabec V.;
RT   "The oncogenic activity of the Src family kinase Hck requires the
RT   cooperative action of the plasma membrane- and lysosome-associated
RT   isoforms.";
RL   Eur. J. Cancer 45:321-327(2009).
RN   [35]
RP   INTERACTION WITH ADAM15.
RX   PubMed=19718658; DOI=10.1002/jcb.22317;
RA   Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.;
RT   "Alternative splicing of ADAM15 regulates its interactions with cellular
RT   SH3 proteins.";
RL   J. Cell. Biochem. 108:877-885(2009).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND SER-462, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [37]
RP   FUNCTION IN ABL1-MEDIATED CELL MIGRATION, AND IDENTIFICATION IN A COMPLEX
RP   WITH ITGB1 AND WITH ABL1.
RX   PubMed=19903482; DOI=10.1016/j.febslet.2009.11.009;
RA   Baruzzi A., Iacobucci I., Soverini S., Lowell C.A., Martinelli G.,
RA   Berton G.;
RT   "c-Abl and Src-family kinases cross-talk in regulation of myeloid cell
RT   migration.";
RL   FEBS Lett. 584:15-21(2010).
RN   [38]
RP   ROLE IN DISEASE, AND FUNCTION IN PHOSPHORYLATION OF THE BCR-ABL FUSION
RP   PROTEIN.
RX   PubMed=20452982; DOI=10.1074/jbc.m109.090043;
RA   Pene-Dumitrescu T., Smithgall T.E.;
RT   "Expression of a Src family kinase in chronic myelogenous leukemia cells
RT   induces resistance to imatinib in a kinase-dependent manner.";
RL   J. Biol. Chem. 285:21446-21457(2010).
RN   [39]
RP   REVIEW ON ROLE IN PHAGOCYTOSIS AND SUBSTRATES.
RX   PubMed=18538446; DOI=10.1016/j.ejcb.2008.03.008;
RA   Guiet R., Poincloux R., Castandet J., Marois L., Labrousse A., Le Cabec V.,
RA   Maridonneau-Parini I.;
RT   "Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from
RT   signaling and actin reorganization to migration and phagocytosis.";
RL   Eur. J. Cell Biol. 87:527-542(2008).
RN   [40]
RP   ROLE IN NEUTROPHIL FUNCTION, AND SIGNALING.
RX   PubMed=21338576; DOI=10.1016/j.abb.2011.02.009;
RA   Zarbock A., Ley K.;
RT   "Protein tyrosine kinases in neutrophil activation and recruitment.";
RL   Arch. Biochem. Biophys. 510:112-119(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-36, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   INTERACTION WITH WDCP.
RX   PubMed=25469238; DOI=10.3892/br.2014.374;
RA   Yokoyama N., Miller W.T.;
RT   "Molecular characterization of WDCP, a novel fusion partner for the
RT   anaplastic lymphoma tyrosine kinase ALK.";
RL   Biomed. Rep. 3:9-13(2015).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [44]
RP   STRUCTURE BY NMR OF 140-245.
RX   PubMed=9109402; DOI=10.1016/s0014-5793(97)00255-x;
RA   Zhang W., Smithgall T.E., Gmeiner W.H.;
RT   "Sequential assignment and secondary structure determination for the Src
RT   homology 2 domain of hematopoietic cellular kinase.";
RL   FEBS Lett. 406:131-135(1997).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 78-526 IN COMPLEX WITH CALCIUM,
RP   AND PHOSPHORYLATION AT TYR-522.
RX   PubMed=9024658; DOI=10.1038/385602a0;
RA   Sicheri F., Moarefi I., Kuriyan J.;
RT   "Crystal structure of the Src family tyrosine kinase Hck.";
RL   Nature 385:602-609(1997).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 81-137.
RX   PubMed=9778343; DOI=10.1021/bi980989q;
RA   Arold S., O'Brien R., Franken P., Strub M.-P., Hoh F., Dumas C.,
RA   Ladbury J.E.;
RT   "RT loop flexibility enhances the specificity of Src family SH3 domains for
RT   HIV-1 Nef.";
RL   Biochemistry 37:14683-14691(1998).
RN   [47]
RP   STRUCTURE BY NMR OF 72-143.
RX   PubMed=9571048; DOI=10.1006/jmbi.1998.1690;
RA   Horita D.A., Baldisseri D.M., Zhang W., Altieri A.S., Smithgall T.E.,
RA   Gmeiner W.H., Byrd R.A.;
RT   "Solution structure of the human Hck SH3 domain and identification of its
RT   ligand binding site.";
RL   J. Mol. Biol. 278:253-265(1998).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 81-522 IN COMPLEX WITH THE
RP   PYRAZOLO PYRIMIDINE-TYPE INHIBITOR PP1, AND PHOSPHORYLATION AT TYR-522.
RX   PubMed=10360180; DOI=10.1016/s1097-2765(00)80357-3;
RA   Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J.;
RT   "Crystal structure of Hck in complex with a Src family-selective tyrosine
RT   kinase inhibitor.";
RL   Mol. Cell 3:639-648(1999).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 81-522 IN COMPLEXES WITH
RP   INHIBITORS A-420983; A-641359 AND A-770041, ACTIVITY REGULATION, AND
RP   PHOSPHORYLATION AT TYR-522.
RX   PubMed=16216497; DOI=10.1016/j.bmcl.2005.09.039;
RA   Burchat A., Borhani D.W., Calderwood D.J., Hirst G.C., Li B.,
RA   Stachlewitz R.F.;
RT   "Discovery of A-770041, a src-family selective orally active lck inhibitor
RT   that prevents organ allograft rejection.";
RL   Bioorg. Med. Chem. Lett. 16:118-122(2006).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 247-513 IN COMPLEX WITH INHIBITOR
RP   PG-1009247.
RX   PubMed=16997556; DOI=10.1016/j.bmcl.2006.08.132;
RA   Sabat M., VanRens J.C., Laufersweiler M.J., Brugel T.A., Maier J.,
RA   Golebiowski A., De B., Easwaran V., Hsieh L.C., Walter R.L., Mekel M.J.,
RA   Evdokimov A., Janusz M.J.;
RT   "The development of 2-benzimidazole substituted pyrimidine based inhibitors
RT   of lymphocyte specific kinase (Lck).";
RL   Bioorg. Med. Chem. Lett. 16:5973-5977(2006).
RN   [51]
RP   STRUCTURE BY NMR OF 61-140 IN COMPLEX WITH PROLINE-RICH SYNTHETIC PEPTIDE.
RX   PubMed=17141806; DOI=10.1016/j.jmb.2006.11.013;
RA   Schmidt H., Hoffmann S., Tran T., Stoldt M., Stangler T., Wiesehan K.,
RA   Willbold D.;
RT   "Solution structure of a Hck SH3 domain ligand complex reveals novel
RT   interaction modes.";
RL   J. Mol. Biol. 365:1517-1532(2007).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 72-256, ACTIVITY REGULATION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=20810664; DOI=10.1074/jbc.m110.145102;
RA   Alvarado J.J., Betts L., Moroco J.A., Smithgall T.E., Yeh J.I.;
RT   "Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory
RT   region supports an SH3-dominant activation mechanism.";
RL   J. Biol. Chem. 285:35455-35461(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 79-138 IN COMPLEX WITH HIV-1 NEF,
RP   AND INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=21625496; DOI=10.1371/journal.pone.0020033;
RA   Breuer S., Schievink S.I., Schulte A., Blankenfeldt W., Fackler O.T.,
RA   Geyer M.;
RT   "Molecular design, functional characterization and structural basis of a
RT   protein inhibitor against the HIV-1 pathogenicity factor Nef.";
RL   PLoS ONE 6:E20033-E20033(2011).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 79-138 IN COMPLEX WITH HIV-1 NEF,
RP   AND INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=21477083; DOI=10.1111/j.1600-0854.2011.01205.x;
RA   Horenkamp F.A., Breuer S., Schulte A., Lulf S., Weyand M., Saksela K.,
RA   Geyer M.;
RT   "Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by
RT   intermolecular domain assembly.";
RL   Traffic 12:867-877(2011).
RN   [55]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-44; LEU-105 AND GLY-399.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase found in hematopoietic
CC       cells that transmits signals from cell surface receptors and plays an
CC       important role in the regulation of innate immune responses, including
CC       neutrophil, monocyte, macrophage and mast cell functions, phagocytosis,
CC       cell survival and proliferation, cell adhesion and migration. Acts
CC       downstream of receptors that bind the Fc region of immunoglobulins,
CC       such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for
CC       IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During
CC       the phagocytic process, mediates mobilization of secretory lysosomes,
CC       degranulation, and activation of NADPH oxidase to bring about the
CC       respiratory burst. Plays a role in the release of inflammatory
CC       molecules. Promotes reorganization of the actin cytoskeleton and actin
CC       polymerization, formation of podosomes and cell protrusions. Inhibits
CC       TP73-mediated transcription activation and TP73-mediated apoptosis.
CC       Phosphorylates CBL in response to activation of immunoglobulin gamma Fc
CC       region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1,
CC       GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS.
CC       {ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:10779760,
CC       ECO:0000269|PubMed:10973280, ECO:0000269|PubMed:11741929,
CC       ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:12411494,
CC       ECO:0000269|PubMed:15010462, ECO:0000269|PubMed:15952790,
CC       ECO:0000269|PubMed:15998323, ECO:0000269|PubMed:17310994,
CC       ECO:0000269|PubMed:17535448, ECO:0000269|PubMed:19114024,
CC       ECO:0000269|PubMed:19903482, ECO:0000269|PubMed:20452982,
CC       ECO:0000269|PubMed:21338576, ECO:0000269|PubMed:7535819,
CC       ECO:0000269|PubMed:8132624, ECO:0000269|PubMed:9406996,
CC       ECO:0000269|PubMed:9407116}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:10779760,
CC         ECO:0000269|PubMed:15998323, ECO:0000269|PubMed:20810664,
CC         ECO:0000269|PubMed:7535819, ECO:0000269|PubMed:8064233,
CC         ECO:0000269|PubMed:8132624, ECO:0000269|PubMed:8995234};
CC   -!- ACTIVITY REGULATION: Subject to autoinhibition, mediated by
CC       intramolecular interactions involving the SH2 and SH3 domains. Kinase
CC       activity is also regulated by phosphorylation at regulatory tyrosine
CC       residues. Phosphorylation at Tyr-411 is required for optimal activity.
CC       Phosphorylation at Tyr-522 inhibits kinase activity. Inhibited by PP1
CC       and A-770041. {ECO:0000269|PubMed:10644735,
CC       ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:10973280,
CC       ECO:0000269|PubMed:16216497, ECO:0000269|PubMed:16849330,
CC       ECO:0000269|PubMed:20810664, ECO:0000269|PubMed:7535819,
CC       ECO:0000269|PubMed:9218412, ECO:0000269|PubMed:9406996}.
CC   -!- SUBUNIT: Interacts (via SH2 domain) with FLT3 (tyrosine
CC       phosphorylated). Interacts with VAV1, WAS and RAPGEF1 (By similarity).
CC       This interaction stimulates its tyrosine-kinase activity. Interacts
CC       with ARRB1 and ARRB2. Interacts with ADAM15. Interacts with FASLG.
CC       Interacts with CBL. Interacts with FCGR1A; the interaction may be
CC       indirect. Interacts with IL6ST. Interacts (via SH3 domain) with ELMO1.
CC       Interacts (via SH3 domain) with TP73. Interacts with YAP1. Interacts
CC       with ABL1 and ITGB1, and thereby recruits ABL1 to activated ITGB1.
CC       Interacts (via SH3 domain) with WDCP. {ECO:0000250,
CC       ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:10360180,
CC       ECO:0000269|PubMed:10973280, ECO:0000269|PubMed:11741929,
CC       ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:15952790,
CC       ECO:0000269|PubMed:16997556, ECO:0000269|PubMed:17141806,
CC       ECO:0000269|PubMed:17310994, ECO:0000269|PubMed:17535448,
CC       ECO:0000269|PubMed:19718658, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:19903482, ECO:0000269|PubMed:25469238,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:8132624,
CC       ECO:0000269|PubMed:9024658, ECO:0000269|PubMed:9406996,
CC       ECO:0000269|PubMed:9407116}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via SH3 domain) with HEV ORF3
CC       protein. {ECO:0000269|PubMed:11518702}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via SH3 domain) with HIV-1
CC       Nef and Vif. {ECO:0000269|PubMed:11278465, ECO:0000269|PubMed:16849330,
CC       ECO:0000269|PubMed:21477083, ECO:0000269|PubMed:21625496,
CC       ECO:0000269|PubMed:9218412}.
CC   -!- INTERACTION:
CC       P08631; O14672: ADAM10; NbExp=2; IntAct=EBI-346340, EBI-1536151;
CC       P08631; O43184: ADAM12; NbExp=2; IntAct=EBI-346340, EBI-2625825;
CC       P08631; Q13444: ADAM15; NbExp=4; IntAct=EBI-346340, EBI-77818;
CC       P08631; P09917: ALOX5; NbExp=2; IntAct=EBI-346340, EBI-79934;
CC       P08631; Q9ULH1: ASAP1; NbExp=2; IntAct=EBI-346340, EBI-346622;
CC       P08631; P00533: EGFR; NbExp=3; IntAct=EBI-346340, EBI-297353;
CC       P08631; Q92556: ELMO1; NbExp=4; IntAct=EBI-346340, EBI-346417;
CC       P08631; P21860: ERBB3; NbExp=2; IntAct=EBI-346340, EBI-720706;
CC       P08631; Q9HD26: GOPC; NbExp=3; IntAct=EBI-346340, EBI-349832;
CC       P08631; P08238: HSP90AB1; NbExp=4; IntAct=EBI-346340, EBI-352572;
CC       P08631; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-346340, EBI-1364;
CC       P08631; P10721: KIT; NbExp=2; IntAct=EBI-346340, EBI-1379503;
CC       P08631; Q6A162: KRT40; NbExp=3; IntAct=EBI-346340, EBI-10171697;
CC       P08631; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-346340, EBI-10172052;
CC       P08631; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-346340, EBI-742948;
CC       P08631; P59046: NLRP12; NbExp=4; IntAct=EBI-346340, EBI-6374637;
CC       P08631; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-346340, EBI-945833;
CC       P08631; Q13177: PAK2; NbExp=2; IntAct=EBI-346340, EBI-1045887;
CC       P08631; Q8WUM4: PDCD6IP; NbExp=4; IntAct=EBI-346340, EBI-310624;
CC       P08631; Q07889: SOS1; NbExp=4; IntAct=EBI-346340, EBI-297487;
CC       P08631; P42768: WAS; NbExp=9; IntAct=EBI-346340, EBI-346375;
CC       P08631; O43516: WIPF1; NbExp=3; IntAct=EBI-346340, EBI-346356;
CC       P08631; P03406: nef; Xeno; NbExp=2; IntAct=EBI-346340, EBI-15672419;
CC       P08631; Q90VU7: nef; Xeno; NbExp=2; IntAct=EBI-346340, EBI-7460704;
CC       P08631; P12504: vif; Xeno; NbExp=3; IntAct=EBI-346340, EBI-779991;
CC       P08631; O92972; Xeno; NbExp=2; IntAct=EBI-346340, EBI-710506;
CC       P08631; P27958; Xeno; NbExp=5; IntAct=EBI-346340, EBI-706378;
CC       P08631-2; O95994: AGR2; NbExp=3; IntAct=EBI-9834454, EBI-712648;
CC       P08631-2; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-9834454, EBI-953896;
CC       P08631-2; P22681: CBL; NbExp=2; IntAct=EBI-9834454, EBI-518228;
CC       P08631-2; A6NC98: CCDC88B; NbExp=3; IntAct=EBI-9834454, EBI-347573;
CC       P08631-2; P78358: CTAG1B; NbExp=3; IntAct=EBI-9834454, EBI-1188472;
CC       P08631-2; Q8WUJ1: CYB5D2; NbExp=3; IntAct=EBI-9834454, EBI-19113794;
CC       P08631-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-9834454, EBI-3867333;
CC       P08631-2; Q5TD97: FHL5; NbExp=3; IntAct=EBI-9834454, EBI-750641;
CC       P08631-2; O43559: FRS3; NbExp=2; IntAct=EBI-9834454, EBI-725515;
CC       P08631-2; Q9HD26-2: GOPC; NbExp=3; IntAct=EBI-9834454, EBI-11102276;
CC       P08631-2; O75031: HSF2BP; NbExp=3; IntAct=EBI-9834454, EBI-7116203;
CC       P08631-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-9834454, EBI-6509505;
CC       P08631-2; Q5T749: KPRP; NbExp=3; IntAct=EBI-9834454, EBI-10981970;
CC       P08631-2; Q15323: KRT31; NbExp=3; IntAct=EBI-9834454, EBI-948001;
CC       P08631-2; O76011: KRT34; NbExp=3; IntAct=EBI-9834454, EBI-1047093;
CC       P08631-2; Q92764: KRT35; NbExp=3; IntAct=EBI-9834454, EBI-1058674;
CC       P08631-2; O76013-2: KRT36; NbExp=3; IntAct=EBI-9834454, EBI-11958506;
CC       P08631-2; Q6A162: KRT40; NbExp=3; IntAct=EBI-9834454, EBI-10171697;
CC       P08631-2; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-9834454, EBI-11959885;
CC       P08631-2; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-9834454, EBI-11749135;
CC       P08631-2; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-9834454, EBI-10172290;
CC       P08631-2; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-9834454, EBI-10171774;
CC       P08631-2; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-9834454, EBI-10172052;
CC       P08631-2; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-9834454, EBI-9996449;
CC       P08631-2; P21741: MDK; NbExp=3; IntAct=EBI-9834454, EBI-722444;
CC       P08631-2; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-9834454, EBI-10172526;
CC       P08631-2; Q13064: MKRN3; NbExp=3; IntAct=EBI-9834454, EBI-2340269;
CC       P08631-2; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-9834454, EBI-11522433;
CC       P08631-2; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-9834454, EBI-22310682;
CC       P08631-2; Q8TAK6: OLIG1; NbExp=2; IntAct=EBI-9834454, EBI-3867416;
CC       P08631-2; Q92569: PIK3R3; NbExp=4; IntAct=EBI-9834454, EBI-79893;
CC       P08631-2; Q58EX7: PLEKHG4; NbExp=3; IntAct=EBI-9834454, EBI-949255;
CC       P08631-2; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-9834454, EBI-302345;
CC       P08631-2; Q05397: PTK2; NbExp=2; IntAct=EBI-9834454, EBI-702142;
CC       P08631-2; Q93062-3: RBPMS; NbExp=3; IntAct=EBI-9834454, EBI-740343;
CC       P08631-2; O14492-2: SH2B2; NbExp=3; IntAct=EBI-9834454, EBI-19952306;
CC       P08631-2; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-9834454, EBI-750487;
CC       P08631-2; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-9834454, EBI-11139477;
CC       P08631-2; Q96NM4-3: TOX2; NbExp=3; IntAct=EBI-9834454, EBI-12815137;
CC       P08631-2; P14373: TRIM27; NbExp=3; IntAct=EBI-9834454, EBI-719493;
CC       P08631-2; Q15654: TRIP6; NbExp=3; IntAct=EBI-9834454, EBI-742327;
CC       P08631-2; O76024: WFS1; NbExp=3; IntAct=EBI-9834454, EBI-720609;
CC       P08631-2; Q8NAM6: ZSCAN4; NbExp=3; IntAct=EBI-9834454, EBI-7252920;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Lysosome. Membrane; Lipid-anchor.
CC       Cell projection, podosome membrane; Lipid-anchor. Cytoplasm, cytosol.
CC       Note=Associated with specialized secretory lysosomes called azurophil
CC       granules. At least half of this isoform is found in the cytoplasm, some
CC       of this fraction is myristoylated.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
CC       {ECO:0000269|PubMed:11904303}; Lipid-anchor
CC       {ECO:0000269|PubMed:11904303}. Membrane, caveola
CC       {ECO:0000269|PubMed:11904303}; Lipid-anchor
CC       {ECO:0000269|PubMed:11904303}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:11904303}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:11904303}. Golgi apparatus
CC       {ECO:0000269|PubMed:11904303}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:11904303}. Lysosome {ECO:0000269|PubMed:11904303}.
CC       Nucleus {ECO:0000269|PubMed:11904303}. Note=20% of this isoform is
CC       associated with caveolae. Localization at the cell membrane and at
CC       caveolae requires palmitoylation at Cys-3. Colocalizes with the actin
CC       cytoskeleton at focal adhesions.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle.
CC       Cytoplasm, cytosol.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=p60-HCK, p61Hck;
CC         IsoId=P08631-1; Sequence=Displayed;
CC       Name=2; Synonyms=p59-HCK, p59Hck;
CC         IsoId=P08631-2; Sequence=VSP_018858;
CC       Name=3;
CC         IsoId=P08631-3; Sequence=VSP_018858, VSP_041926;
CC       Name=4;
CC         IsoId=P08631-4; Sequence=VSP_041926;
CC   -!- TISSUE SPECIFICITY: Detected in monocytes and neutrophils (at protein
CC       level). Expressed predominantly in cells of the myeloid and B-lymphoid
CC       lineages. Highly expressed in granulocytes. Detected in tonsil.
CC       {ECO:0000269|PubMed:3453117, ECO:0000269|PubMed:8064233,
CC       ECO:0000269|PubMed:8995234}.
CC   -!- INDUCTION: Up-regulated during myeloid cell differentiation. The
CC       highest levels are detected in fully differentiated phagocytes. Up-
CC       regulated by IL2. {ECO:0000269|PubMed:10779760,
CC       ECO:0000269|PubMed:8995234}.
CC   -!- DOMAIN: The SH3 domain mediates binding to HIV-1 Nef.
CC   -!- PTM: Phosphorylated on several tyrosine residues. Autophosphorylated.
CC       Becomes rapidly phosphorylated upon activation of the immunoglobulin
CC       receptors FCGR1A and FCGR2A. Phosphorylation by the BCR-ABL fusion
CC       protein mediates activation of HCK. Phosphorylation at Tyr-411
CC       increases kinase activity. Phosphorylation at Tyr-522 inhibits kinase
CC       activity. Kinase activity is not required for phosphorylation at Tyr-
CC       522, suggesting that this site is a target of other kinases.
CC       {ECO:0000269|PubMed:10360180, ECO:0000269|PubMed:10644735,
CC       ECO:0000269|PubMed:10779760, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:16216497,
CC       ECO:0000269|PubMed:8064233, ECO:0000269|PubMed:9024658,
CC       ECO:0000269|PubMed:9406996}.
CC   -!- PTM: Ubiquitinated by CBL, leading to its degradation via the
CC       proteasome. {ECO:0000269|PubMed:11896602}.
CC   -!- PTM: Isoform 2 palmitoylation at position 2 requires prior
CC       myristoylation. Palmitoylation at position 3 is required for caveolar
CC       localization of isoform 2. {ECO:0000269|PubMed:7791757}.
CC   -!- DISEASE: Note=Aberrant activation of HCK by HIV-1 protein Nef enhances
CC       HIV-1 replication and contributes to HIV-1 pathogenicity.
CC   -!- DISEASE: Note=Aberrant activation of HCK, e.g. by the BCR-ABL fusion
CC       protein, promotes cancer cell proliferation.
CC   -!- MISCELLANEOUS: [Isoform 1]: Initiates from a CTG codon.
CC   -!- MISCELLANEOUS: [Isoform 4]: Initiates from a CTG codon. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52643.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAF82585.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M16591; AAA52643.1; ALT_FRAME; mRNA.
DR   EMBL; M16592; AAA52644.1; -; mRNA.
DR   EMBL; AK026432; BAB15482.1; -; mRNA.
DR   EMBL; AK289896; BAF82585.1; ALT_INIT; mRNA.
DR   EMBL; AK298726; BAG60878.1; -; mRNA.
DR   EMBL; AL353092; CAI19694.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19694.1; JOINED; Genomic_DNA.
DR   EMBL; AL353092; CAI19695.1; -; Genomic_DNA.
DR   EMBL; AL049539; CAI19695.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22966.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22966.1; JOINED; Genomic_DNA.
DR   EMBL; AL049539; CAI22967.1; -; Genomic_DNA.
DR   EMBL; AL353092; CAI22967.1; JOINED; Genomic_DNA.
DR   EMBL; CH471077; EAW76392.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76393.1; -; Genomic_DNA.
DR   EMBL; BC014435; AAH14435.2; -; mRNA.
DR   EMBL; BC094847; AAH94847.2; -; mRNA.
DR   EMBL; BC108930; AAI08931.2; -; mRNA.
DR   EMBL; BC108931; AAI08932.2; -; mRNA.
DR   EMBL; BC113854; AAI13855.2; -; mRNA.
DR   EMBL; BC114463; AAI14464.2; -; mRNA.
DR   EMBL; X58741; CAA41565.2; -; Genomic_DNA.
DR   EMBL; X58742; CAA41565.2; JOINED; Genomic_DNA.
DR   EMBL; X58743; CAA41565.2; JOINED; Genomic_DNA.
DR   CCDS; CCDS33460.1; -. [P08631-1]
DR   CCDS; CCDS54453.1; -. [P08631-4]
DR   CCDS; CCDS54455.1; -. [P08631-2]
DR   CCDS; CCDS54456.1; -. [P08631-3]
DR   PIR; A27811; TVHUHC.
DR   PIR; A41263; A41263.
DR   RefSeq; NP_001165600.1; NM_001172129.1. [P08631-2]
DR   RefSeq; NP_001165601.1; NM_001172130.1. [P08631-4]
DR   RefSeq; NP_001165602.1; NM_001172131.1. [P08631-3]
DR   RefSeq; NP_001165604.1; NM_001172133.1. [P08631-2]
DR   RefSeq; NP_002101.2; NM_002110.3. [P08631-1]
DR   PDB; 1AD5; X-ray; 2.60 A; A/B=79-526.
DR   PDB; 1BU1; X-ray; 2.60 A; A/B/C/D/E/F=81-137.
DR   PDB; 1QCF; X-ray; 2.00 A; A=81-526.
DR   PDB; 2C0I; X-ray; 2.30 A; A/B=81-526.
DR   PDB; 2C0O; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 2C0T; X-ray; 2.15 A; A/B=81-526.
DR   PDB; 2HCK; X-ray; 3.00 A; A/B=79-526.
DR   PDB; 2HK5; X-ray; 2.00 A; A=247-514.
DR   PDB; 2OI3; NMR; -; A=61-141.
DR   PDB; 2OJ2; NMR; -; A=61-141.
DR   PDB; 3HCK; NMR; -; A=140-245.
DR   PDB; 3NHN; X-ray; 2.61 A; A=72-256.
DR   PDB; 3RBB; X-ray; 2.35 A; B/D=79-138.
DR   PDB; 3REA; X-ray; 2.00 A; B/D=79-138.
DR   PDB; 3REB; X-ray; 3.45 A; B/D=79-138.
DR   PDB; 3VRY; X-ray; 2.48 A; A/B=81-526.
DR   PDB; 3VRZ; X-ray; 2.22 A; A/B=81-526.
DR   PDB; 3VS0; X-ray; 2.93 A; A/B=81-526.
DR   PDB; 3VS1; X-ray; 2.46 A; A/B=81-526.
DR   PDB; 3VS2; X-ray; 2.61 A; A/B=81-526.
DR   PDB; 3VS3; X-ray; 2.17 A; A/B=81-526.
DR   PDB; 3VS4; X-ray; 2.75 A; A/B=81-526.
DR   PDB; 3VS5; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 3VS6; X-ray; 2.37 A; A/B=81-526.
DR   PDB; 3VS7; X-ray; 3.00 A; A/B=81-526.
DR   PDB; 4HCK; NMR; -; A=72-143.
DR   PDB; 4LUD; X-ray; 2.85 A; A/B=81-526.
DR   PDB; 4LUE; X-ray; 3.04 A; A/B=81-526.
DR   PDB; 4ORZ; X-ray; 2.00 A; A=77-138.
DR   PDB; 4U5W; X-ray; 1.86 A; B/D=72-242.
DR   PDB; 5H09; X-ray; 1.95 A; A=81-526.
DR   PDB; 5H0B; X-ray; 1.65 A; A=81-526.
DR   PDB; 5H0E; X-ray; 2.10 A; A=81-526.
DR   PDB; 5H0G; X-ray; 1.80 A; A=81-526.
DR   PDB; 5H0H; X-ray; 1.72 A; A=81-526.
DR   PDB; 5HCK; NMR; -; A=72-143.
DR   PDB; 5NUH; X-ray; 2.78 A; C/D=79-138.
DR   PDB; 5ZJ6; X-ray; 1.70 A; A/B=242-521.
DR   PDBsum; 1AD5; -.
DR   PDBsum; 1BU1; -.
DR   PDBsum; 1QCF; -.
DR   PDBsum; 2C0I; -.
DR   PDBsum; 2C0O; -.
DR   PDBsum; 2C0T; -.
DR   PDBsum; 2HCK; -.
DR   PDBsum; 2HK5; -.
DR   PDBsum; 2OI3; -.
DR   PDBsum; 2OJ2; -.
DR   PDBsum; 3HCK; -.
DR   PDBsum; 3NHN; -.
DR   PDBsum; 3RBB; -.
DR   PDBsum; 3REA; -.
DR   PDBsum; 3REB; -.
DR   PDBsum; 3VRY; -.
DR   PDBsum; 3VRZ; -.
DR   PDBsum; 3VS0; -.
DR   PDBsum; 3VS1; -.
DR   PDBsum; 3VS2; -.
DR   PDBsum; 3VS3; -.
DR   PDBsum; 3VS4; -.
DR   PDBsum; 3VS5; -.
DR   PDBsum; 3VS6; -.
DR   PDBsum; 3VS7; -.
DR   PDBsum; 4HCK; -.
DR   PDBsum; 4LUD; -.
DR   PDBsum; 4LUE; -.
DR   PDBsum; 4ORZ; -.
DR   PDBsum; 4U5W; -.
DR   PDBsum; 5H09; -.
DR   PDBsum; 5H0B; -.
DR   PDBsum; 5H0E; -.
DR   PDBsum; 5H0G; -.
DR   PDBsum; 5H0H; -.
DR   PDBsum; 5HCK; -.
DR   PDBsum; 5NUH; -.
DR   PDBsum; 5ZJ6; -.
DR   AlphaFoldDB; P08631; -.
DR   BMRB; P08631; -.
DR   SMR; P08631; -.
DR   BioGRID; 109305; 153.
DR   DIP; DIP-1051N; -.
DR   ELM; P08631; -.
DR   IntAct; P08631; 155.
DR   MINT; P08631; -.
DR   STRING; 9606.ENSP00000444986; -.
DR   BindingDB; P08631; -.
DR   ChEMBL; CHEMBL3234; -.
DR   DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB04216; Quercetin.
DR   DrugCentral; P08631; -.
DR   GuidetoPHARMACOLOGY; 2032; -.
DR   GlyGen; P08631; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P08631; -.
DR   PhosphoSitePlus; P08631; -.
DR   SwissPalm; P08631; -.
DR   BioMuta; HCK; -.
DR   DMDM; 20141296; -.
DR   EPD; P08631; -.
DR   jPOST; P08631; -.
DR   MassIVE; P08631; -.
DR   MaxQB; P08631; -.
DR   PaxDb; P08631; -.
DR   PeptideAtlas; P08631; -.
DR   PRIDE; P08631; -.
DR   ProteomicsDB; 52142; -. [P08631-1]
DR   ProteomicsDB; 52143; -. [P08631-2]
DR   ProteomicsDB; 52144; -. [P08631-3]
DR   ProteomicsDB; 52145; -. [P08631-4]
DR   Antibodypedia; 3921; 602 antibodies from 36 providers.
DR   DNASU; 3055; -.
DR   Ensembl; ENST00000375852.5; ENSP00000365012.3; ENSG00000101336.18. [P08631-1]
DR   Ensembl; ENST00000375862.7; ENSP00000365022.3; ENSG00000101336.18. [P08631-4]
DR   Ensembl; ENST00000518730.5; ENSP00000427757.1; ENSG00000101336.18. [P08631-3]
DR   Ensembl; ENST00000520553.5; ENSP00000429848.1; ENSG00000101336.18. [P08631-2]
DR   Ensembl; ENST00000629881.2; ENSP00000486627.1; ENSG00000101336.18. [P08631-2]
DR   GeneID; 3055; -.
DR   KEGG; hsa:3055; -.
DR   MANE-Select; ENST00000375852.5; ENSP00000365012.3; NM_002110.5; NP_002101.2.
DR   UCSC; uc002wxi.4; human. [P08631-1]
DR   CTD; 3055; -.
DR   DisGeNET; 3055; -.
DR   GeneCards; HCK; -.
DR   HGNC; HGNC:4840; HCK.
DR   HPA; ENSG00000101336; Tissue enhanced (lymphoid).
DR   MIM; 142370; gene.
DR   neXtProt; NX_P08631; -.
DR   OpenTargets; ENSG00000101336; -.
DR   PharmGKB; PA29216; -.
DR   VEuPathDB; HostDB:ENSG00000101336; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158738; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P08631; -.
DR   OMA; QKLTFPC; -.
DR   PhylomeDB; P08631; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P08631; -.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF).
DR   Reactome; R-HSA-9705462; Inactivation of CSF3 (G-CSF) signaling.
DR   Reactome; R-HSA-9706374; FLT3 signaling through SRC family kinases.
DR   SignaLink; P08631; -.
DR   SIGNOR; P08631; -.
DR   BioGRID-ORCS; 3055; 12 hits in 1101 CRISPR screens.
DR   ChiTaRS; HCK; human.
DR   EvolutionaryTrace; P08631; -.
DR   GeneWiki; HCK; -.
DR   GenomeRNAi; 3055; -.
DR   Pharos; P08631; Tclin.
DR   PRO; PR:P08631; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P08631; protein.
DR   Bgee; ENSG00000101336; Expressed in monocyte and 175 other tissues.
DR   ExpressionAtlas; P08631; baseline and differential.
DR   Genevisible; P08631; HS.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0042995; C:cell projection; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IMP:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0030133; C:transport vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008289; F:lipid binding; EXP:DisProt.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; TAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0002758; P:innate immune response-activating signal transduction; TAS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0043299; P:leukocyte degranulation; TAS:UniProtKB.
DR   GO; GO:0002522; P:leukocyte migration involved in immune response; TAS:UniProtKB.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0051179; P:localization; EXP:DisProt.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0050764; P:regulation of phagocytosis; IMP:UniProtKB.
DR   GO; GO:0071801; P:regulation of podosome assembly; IDA:UniProtKB.
DR   GO; GO:0045728; P:respiratory burst after phagocytosis; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10363; SH2_Src_HCK; 1.
DR   DisProt; DP02383; -.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035851; HCK_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing; ATP-binding;
KW   Cell junction; Cell membrane; Cell projection; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; Exocytosis; Golgi apparatus;
KW   Host-virus interaction; Immunity; Inflammatory response; Innate immunity;
KW   Kinase; Lipoprotein; Lysosome; Membrane; Myristate; Nucleotide-binding;
KW   Nucleus; Palmitate; Phagocytosis; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..526
FT                   /note="Tyrosine-protein kinase HCK"
FT                   /id="PRO_0000024433"
FT   DOMAIN          78..138
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          144..241
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          262..515
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..20
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        381
FT                   /note="Proton acceptor"
FT   BINDING         268..276
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         290
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         36
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         51
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11896602"
FT   MOD_RES         202
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         209
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P08103"
FT   MOD_RES         411
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10644735,
FT                   ECO:0000269|PubMed:11896602"
FT   MOD_RES         462
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         522
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10360180,
FT                   ECO:0000269|PubMed:10644735, ECO:0000269|PubMed:11896602,
FT                   ECO:0000269|PubMed:16216497, ECO:0000269|PubMed:9024658"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:7791757"
FT   VAR_SEQ         1..21
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3453117"
FT                   /id="VSP_018858"
FT   VAR_SEQ         76
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041926"
FT   VARIANT         44
FT                   /note="A -> T (in dbSNP:rs56029200)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041707"
FT   VARIANT         105
FT                   /note="M -> L (in dbSNP:rs55722810)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041708"
FT   VARIANT         399
FT                   /note="D -> G (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041709"
FT   VARIANT         502
FT                   /note="P -> Q (in dbSNP:rs17093828)"
FT                   /id="VAR_033836"
FT   MUTAGEN         3
FT                   /note="G->C: Slight palmitoylation, cytoplasmic and
FT                   caveolar localization; in isoform 1;."
FT                   /evidence="ECO:0000269|PubMed:11904303,
FT                   ECO:0000269|PubMed:7791757"
FT   MUTAGEN         3
FT                   /note="G->S: Abolishes palmitoylation and localization at
FT                   the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:11904303,
FT                   ECO:0000269|PubMed:7791757"
FT   MUTAGEN         23
FT                   /note="G->A: Myristoylation and palmitoylation are
FT                   abolished, leading to entirely cytoplasmic localization; in
FT                   isoform 2."
FT                   /evidence="ECO:0000269|PubMed:7791757"
FT   MUTAGEN         24
FT                   /note="C->S: Palmitoylation is abolished, some cytoplasmic
FT                   and no calveolar localization; in isoform 2."
FT                   /evidence="ECO:0000269|PubMed:7791757"
FT   MUTAGEN         290
FT                   /note="K->E: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11896602"
FT   MUTAGEN         305
FT                   /note="E->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10644735"
FT   MUTAGEN         381
FT                   /note="D->E: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15998323"
FT   MUTAGEN         411
FT                   /note="Y->A: Reduced catalytic activity and higher affinity
FT                   for target peptides."
FT                   /evidence="ECO:0000269|PubMed:10644735"
FT   MUTAGEN         522
FT                   /note="Y->F: Constitutively activated kinase, leading to
FT                   cellular transformation."
FT                   /evidence="ECO:0000269|PubMed:10092522,
FT                   ECO:0000269|PubMed:11896602"
FT   CONFLICT        24
FT                   /note="C -> S (in Ref. 1; AAA52643)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="N -> D (in Ref. 3; BAF82585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        144
FT                   /note="W -> R (in Ref. 3; BAB15482)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        168
FT                   /note="F -> Y (in Ref. 3; BAF82585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        378
FT                   /note="I -> T (in Ref. 6; AAI13855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        488
FT                   /note="N -> S (in Ref. 3; BAF82585)"
FT                   /evidence="ECO:0000305"
FT   STRAND          82..85
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          93..96
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          99..102
FT                   /evidence="ECO:0007829|PDB:5H0H"
FT   STRAND          104..111
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          114..122
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          127..129
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           130..132
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           136..138
FT                   /evidence="ECO:0007829|PDB:2OI3"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          145..148
FT                   /evidence="ECO:0007829|PDB:3VS2"
FT   HELIX           151..159
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          168..172
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          174..176
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          180..188
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   TURN            189..191
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          192..202
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:4U5W"
FT   STRAND          208..211
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          215..218
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           219..228
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   TURN            252..255
FT                   /evidence="ECO:0007829|PDB:2HCK"
FT   HELIX           259..261
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          262..270
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          272..281
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   TURN            282..284
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          285..292
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          294..297
FT                   /evidence="ECO:0007829|PDB:3VS3"
FT   HELIX           299..309
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          320..324
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          326..328
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          330..333
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           341..345
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           355..374
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           384..386
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          395..397
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           402..405
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           410..413
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          416..419
FT                   /evidence="ECO:0007829|PDB:1QCF"
FT   HELIX           421..423
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           426..431
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           436..451
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   TURN            452..454
FT                   /evidence="ECO:0007829|PDB:2HK5"
FT   STRAND          457..460
FT                   /evidence="ECO:0007829|PDB:1AD5"
FT   HELIX           463..471
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          480..482
FT                   /evidence="ECO:0007829|PDB:3VS6"
FT   HELIX           484..493
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           498..500
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   HELIX           504..512
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   TURN            513..518
FT                   /evidence="ECO:0007829|PDB:5H0B"
FT   STRAND          521..523
FT                   /evidence="ECO:0007829|PDB:1QCF"
FT   INIT_MET        P08631-2:1
FT                   /note="Removed"
FT                   /evidence="ECO:0000305"
FT   LIPID           P08631-2:2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:7791757"
FT   LIPID           P08631-2:3
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:7791757"
SQ   SEQUENCE   526 AA;  59600 MW;  847E877A0A641725 CRC64;
     MGGRSSCEDP GCPRDEERAP RMGCMKSKFL QVGGNTFSKT ETSASPHCPV YVPDPTSTIK
     PGPNSHNSNT PGIREAGSED IIVVALYDYE AIHHEDLSFQ KGDQMVVLEE SGEWWKARSL
     ATRKEGYIPS NYVARVDSLE TEEWFFKGIS RKDAERQLLA PGNMLGSFMI RDSETTKGSY
     SLSVRDYDPR QGDTVKHYKI RTLDNGGFYI SPRSTFSTLQ ELVDHYKKGN DGLCQKLSVP
     CMSSKPQKPW EKDAWEIPRE SLKLEKKLGA GQFGEVWMAT YNKHTKVAVK TMKPGSMSVE
     AFLAEANVMK TLQHDKLVKL HAVVTKEPIY IITEFMAKGS LLDFLKSDEG SKQPLPKLID
     FSAQIAEGMA FIEQRNYIHR DLRAANILVS ASLVCKIADF GLARVIEDNE YTAREGAKFP
     IKWTAPEAIN FGSFTIKSDV WSFGILLMEI VTYGRIPYPG MSNPEVIRAL ERGYRMPRPE
     NCPEELYNIM MRCWKNRPEE RPTFEYIQSV LDDFYTATES QYQQQP
//
